Managing Alzheimer's Disease Now and in the Future: A Guide for Managed Care Web Activity

• Release Date: February 15, 2018
• Expiration Date: August 31, 2019
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health Click here for biography James Kenney, Jr., RPh, MBA Manager, Specialty and Pharmacy Contracts Harvard Pilgrim Health Care Click here for biography Marwan Sabbagh, MD, FAAN, CCRI Karsten Solheim Chair of Dementia Professor of Neurology Director of the Alzheimer's and Memory Disorders Division Barrow Neurological Institute Click here for biography

TARGET AUDIENCE

• Managed care pharmacy directors, clinical pharmacists, quality directors, specialty pharmacists, medical directors, care managers, registered nurses, and other managed care and payer organization professionals

STATEMENT OF NEED/PROGRAM OVERVIEW

Alzheimer’s disease (AD) represents a significant driver of morbidity and mortality in the United States, despite being overshadowed by other predominant conditions for which more effective treatment modalities exist. The incidence and mortality associated with the disease is increasing, indicating a key area of concern for managed care stakeholders. This educational activity is designed to improve the knowledge and competence of managed care professionals regarding the management of patients with AD.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Characterize the clinical and economic burden of AD in terms of incidence and prevalence as well as direct and indirect costs
• Describe various diagnostic tools for AD and evaluate their respective benefits and disadvantages for standardized use among network providers
• Describe the impact of care coordination in AD in terms of patient quality of life and disease outcomes
• Implement plan-wide initiatives to better coordinate care for AD among primary and ancillary providers in acute and long-term settings
• Appraise the clinical benefits of novel therapeutics addressing neuropsychological symptoms and disease modifying agents in the management of AD
• Develop formulary positioning and benefit design strategies for emerging AD therapies that encourage appropriate utilization while facilitating patient access and adherence
• Outline the components and benefits of an effective medication therapy management (MTM) program for AD
• Characterize the role of specialty pharmacy in supporting appropriate utilization and administration of emerging therapies for AD

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008162-9999-18-152-H01-P

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of February 15, 2018, through August 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.